Symbols / XRTX
XRTX Chart
About
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease. Its drug development programs include XRx-026, which is in the third phase for the treatment of gout; XRx-008, which is in the second phase to treat autosomal dominant polycystic kidney disease; XRx-101, which is in the second phase to treat acute kidney injury associated with respiratory virus infection; and XRX-225, which is in the preclinical stage for the treatment of type 2 diabetic nephropathy. It has a license agreement with the University of Florida Research Foundation, Inc. for the use of uric acid lowering agent to treat insulin resistance. The company is based in Calgary, Canada.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 2.85M |
| Enterprise Value | 1.72M | Income | -1.94M | Sales | — |
| Book/sh | 0.38 | Cash/sh | 0.17 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | 0.51 | PEG | — |
| P/S | — | P/B | 1.08 | P/C | — |
| EV/EBITDA | -0.70 | EV/Sales | — | Quick Ratio | 1.45 |
| Current Ratio | 1.62 | Debt/Eq | 2.99 | LT Debt/Eq | — |
| EPS (ttm) | -0.40 | EPS next Y | 0.80 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-14 | ROA | -45.32% |
| ROE | -94.63% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 6.96M |
| Shs Float | 6.25M | Short Float | 1.58% | Short Ratio | 0.36 |
| Short Interest | — | 52W High | 1.41 | 52W Low | 0.37 |
| Beta | 0.15 | Avg Volume | 144.01K | Volume | 74.44K |
| Target Price | $14.12 | Recom | None | Prev Close | $0.40 |
| Price | $0.41 | Change | 1.49% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$14.12
Mean price target
2. Current target
$0.41
Latest analyst target
3. DCF / Fair value
$-6.04
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.41
Low
$14.12
High
$14.12
Mean
$14.12
- Huge gout genetics study highlights target in kidney disease research - Stock Titan Wed, 31 Dec 2025 08
- XRTX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI Wed, 18 Feb 2026 05
- XORTX Therapeutics stock soars after acquiring renal therapeutic program - Investing.com South Africa Fri, 17 Oct 2025 07
- XORTX Extends Closing Of Renal Anti-Fibrotic Therapeutic Program Acquisition; Stock Soars - Nasdaq hu, 05 Feb 2026 08
- XRTX Stock Surges Over 40% on Bold Move to Snag Promising Kidney Treatment Tech - RagingBull Fri, 17 Oct 2025 07
- symbol__ Stock Quote Price and Forecast - CNN Fri, 22 Dec 2023 11
- $3.0M Acquisition: XORTX Secures VB4‑P5 Renal Anti‑Fibrotic Program from Vectus, Pre‑IND - Stock Titan Fri, 17 Oct 2025 07
- XORTX Announces Pricing of US$1.1 Million Registered Direct Offering - Yahoo Finance ue, 21 Oct 2025 07
- Breakout Move: Is XRTX stock undervalued right now - Market Activity Summary & AI Forecasted Entry/Exit Points - baoquankhu1.vn Sun, 22 Feb 2026 03
- Xortx Therapeutics: Micro-cap roller coaster as XRTX tests the patience of speculative biotech inves - AD HOC NEWS Wed, 21 Jan 2026 08
- 1,746,631 shares at $0.63: XORTX (NASDAQ: XRTX) prices registered direct offering - Stock Titan ue, 21 Oct 2025 07
- What is the current Price Target and Forecast for XORTX Therapeutics (XRTX) - Zacks Investment Research Wed, 31 Aug 2022 19
- XRTX Stock Price and Chart — TSXV:XRTX - TradingView Fri, 05 Nov 2021 09
- XORTX (NASDAQ: XRTX) gets $1.00 bid-price notice; 180-day window, listing intact - Stock Titan Mon, 20 Oct 2025 07
- XORTX Reprices Balance of Warrants Issued in Connection with October 2021 US IPO - ChartMill Fri, 17 May 2024 07
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership | Value |
|---|---|---|---|---|---|---|---|---|---|
| 0 | — | — | — | Davies Foss (Krysta) | Director of Issuer | — | 2025-12-31 00:00:00 | D | nan |
| 1 | 3654 | — | Disposition in the public market at price 1.00 per share. | Van Damme (Paul Joseph) | Director of Issuer | — | 2025-10-17 00:00:00 | D | 3650.0 |
| 2 | 3132 | — | Disposition in the public market at price 0.98 per share. | Van Damme (Paul Joseph) | Director of Issuer | — | 2025-10-17 00:00:00 | D | 3081.0 |
| 3 | 8191 | — | Acquisition in the public market at price 0.74 per share. | Davidoff, Allen Warren | Director of Issuer | — | 2025-07-22 00:00:00 | D | 6020.0 |
| 4 | 300 | — | Acquisition in the public market at price 0.87 per share. | Davidoff, Allen Warren | Director of Issuer | — | 2025-06-23 00:00:00 | D | 262.0 |
| 5 | 500 | — | Acquisition in the public market at price 0.86 per share. | Davidoff, Allen Warren | Director of Issuer | — | 2025-06-23 00:00:00 | D | 429.0 |
| 6 | 2000 | — | Acquisition in the public market at price 1.02 per share. | Davidoff, Allen Warren | Director of Issuer | — | 2025-05-14 00:00:00 | D | 2040.0 |
| 7 | 2000 | — | Acquisition in the public market at price 1.02 per share. | Davidoff, Allen Warren | Director of Issuer | — | 2025-05-14 00:00:00 | D | 2044.0 |
| 8 | 1000 | — | Acquisition in the public market at price 0.73 per share. | Davidoff, Allen Warren | Director of Issuer | — | 2025-05-12 00:00:00 | D | 733.0 |
| 9 | 300 | — | Acquisition in the public market at price 1.04 per share. | Davidoff, Allen Warren | Director of Issuer | — | 2025-05-12 00:00:00 | D | 313.0 |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -4.68M | -9.54M | -12.70M | -4.23M |
| TotalUnusualItems | 683.07K | 3.63M | 2.47M | 1.34M |
| TotalUnusualItemsExcludingGoodwill | 683.07K | 3.63M | 2.47M | 1.34M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -3.31M | -2.16M | -7.72M | -1.58M |
| ReconciledDepreciation | 117.27K | 139.69K | 58.15K | 14.27K |
| EBITDA | -4.00M | -5.91M | -10.23M | -2.90M |
| EBIT | -4.12M | -6.05M | -10.29M | -2.91M |
| NetInterestIncome | 121.91K | 253.54K | 103.59K | -4.45K |
| InterestExpense | 0.00 | 4.39K | ||
| InterestIncome | 101.37K | |||
| NormalizedIncome | -4.00M | -5.79M | -10.19M | -2.92M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -3.31M | -2.16M | -7.72M | -1.58M |
| TotalExpenses | 4.12M | 6.05M | 10.29M | 2.91M |
| DilutedAverageShares | 2.88M | 1.98M | 1.48M | 1.09M |
| BasicAverageShares | 2.88M | 1.98M | 1.48M | 1.09M |
| DilutedEPS | -1.15 | -1.09 | -4.71 | -1.20 |
| BasicEPS | -1.15 | -1.09 | -4.71 | -1.20 |
| DilutedNIAvailtoComStockholders | -3.31M | -2.16M | -7.72M | -1.58M |
| NetIncomeCommonStockholders | -3.31M | -2.16M | -7.72M | -1.58M |
| NetIncome | -3.31M | -2.16M | -7.72M | -1.58M |
| NetIncomeIncludingNoncontrollingInterests | -3.31M | -2.16M | -7.72M | -1.58M |
| NetIncomeContinuousOperations | -3.31M | -2.16M | -7.72M | -1.58M |
| PretaxIncome | -3.31M | -2.16M | -7.72M | -1.58M |
| OtherIncomeExpense | 683.07K | 3.63M | 2.47M | 1.34M |
| SpecialIncomeCharges | -279.03K | 0.00 | -926.46K | -1.29M |
| ImpairmentOfCapitalAssets | 0.00 | |||
| RestructuringAndMergernAcquisition | 279.03K | 0.00 | 926.46K | 1.29M |
| GainOnSaleOfSecurity | 962.10K | 3.63M | 3.39M | 2.62M |
| NetNonOperatingInterestIncomeExpense | 121.91K | 253.54K | 103.59K | -4.45K |
| TotalOtherFinanceCost | -121.91K | -253.54K | -103.59K | 4.45K |
| InterestExpenseNonOperating | 0.00 | 4.39K | ||
| InterestIncomeNonOperating | 101.37K | |||
| OperatingIncome | -4.12M | -6.05M | -10.29M | -2.91M |
| OperatingExpense | 4.12M | 6.05M | 10.29M | 2.91M |
| OtherOperatingExpenses | 1.53M | 1.26M | 1.07M | 602.57K |
| DepreciationAmortizationDepletionIncomeStatement | 117.27K | 139.69K | 58.15K | 14.27K |
| DepreciationAndAmortizationInIncomeStatement | 117.27K | 139.69K | 58.15K | 14.27K |
| Amortization | 31.07K | 66.63K | 17.08K | 14.27K |
| AmortizationOfIntangiblesIncomeStatement | 31.07K | 66.63K | 17.08K | 14.27K |
| DepreciationIncomeStatement | 86.20K | 73.06K | 41.07K | 0.00 |
| ResearchAndDevelopment | 183.83K | 2.42M | 6.76M | 677.58K |
| SellingGeneralAndAdministration | 2.28M | 2.23M | 2.40M | 1.62M |
| GeneralAndAdministrativeExpense | 2.28M | 2.23M | 2.40M | 1.62M |
| OtherGandA | 1.99M | 1.93M | 1.79M | 1.17M |
| SalariesAndWages | 290.67K | 300.39K | 610.51K | 445.79K |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 3.48M | 2.00M | 1.67M | 1.44M |
| ShareIssued | 3.48M | 2.00M | 1.67M | 1.44M |
| TotalDebt | 38.78K | 11.51K | 77.60K | 0.00 |
| TangibleBookValue | 3.15M | 4.47M | 6.80M | 13.00M |
| InvestedCapital | 3.34M | 4.64M | 7.00M | 13.20M |
| WorkingCapital | 1.92M | 3.24M | 9.38M | 15.36M |
| NetTangibleAssets | 3.15M | 4.47M | 6.80M | 13.00M |
| CapitalLeaseObligations | 38.78K | 11.51K | 77.60K | 0.00 |
| CommonStockEquity | 3.34M | 4.64M | 7.00M | 13.20M |
| TotalCapitalization | 3.34M | 4.64M | 7.00M | 13.20M |
| TotalEquityGrossMinorityInterest | 3.34M | 4.64M | 7.00M | 13.20M |
| StockholdersEquity | 3.34M | 4.64M | 7.00M | 13.20M |
| OtherEquityInterest | 6.06M | 5.49M | 6.22M | 5.02M |
| GainsLossesNotAffectingRetainedEarnings | -52.60K | -52.60K | -52.60K | 75.54K |
| OtherEquityAdjustments | -52.60K | -52.60K | -52.60K | 75.54K |
| RetainedEarnings | -21.17M | -17.85M | -15.70M | -7.98M |
| CapitalStock | 18.49M | 17.06M | 16.52M | 16.09M |
| CommonStock | 18.49M | 17.06M | 16.52M | 16.09M |
| TotalLiabilitiesNetMinorityInterest | 757.99K | 825.94K | 5.38M | 4.18M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 3.87M | 3.63M |
| DerivativeProductLiabilities | 531.00K | 3.85M | 3.63M | |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 11.51K | 0.00 | |
| LongTermCapitalLeaseObligation | 0.00 | 11.51K | 0.00 | |
| CurrentLiabilities | 757.99K | 825.94K | 1.51M | 552.95K |
| OtherCurrentLiabilities | 572.00K | 531.00K | ||
| CurrentDebtAndCapitalLeaseObligation | 38.78K | 11.51K | 66.09K | |
| CurrentCapitalLeaseObligation | 38.78K | 11.51K | 66.09K | 0.00 |
| PayablesAndAccruedExpenses | 147.21K | 283.43K | 1.45M | 552.95K |
| CurrentAccruedExpenses | 63.19K | 87.61K | 151.41K | 228.99K |
| Payables | 84.02K | 195.81K | 1.29M | 323.96K |
| AccountsPayable | 84.02K | 195.81K | 1.29M | 323.96K |
| TotalAssets | 4.09M | 5.47M | 12.37M | 17.38M |
| TotalNonCurrentAssets | 1.42M | 1.40M | 1.48M | 1.47M |
| NonCurrentAccountsReceivable | 1.20M | 1.20M | 1.19M | 1.27M |
| GoodwillAndOtherIntangibleAssets | 183.11K | 175.25K | 199.83K | 202.12K |
| OtherIntangibleAssets | 183.11K | 175.25K | 199.83K | 202.12K |
| NetPPE | 34.72K | 23.93K | 92.68K | 0.00 |
| AccumulatedDepreciation | -200.21K | -114.00K | -40.94K | 0.00 |
| GrossPPE | 234.93K | 137.93K | 133.62K | 0.00 |
| OtherProperties | 23.34K | 23.34K | 19.03K | |
| BuildingsAndImprovements | 211.59K | 114.59K | 114.59K | 0.00 |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 2.68M | 4.07M | 10.90M | 15.91M |
| CurrentDeferredAssets | 0.00 | 323.44K | 0.00 | 0.00 |
| PrepaidAssets | 185.41K | 236.97K | 379.62K | 1.00M |
| Receivables | 17.64K | 60.71K | 81.75K | 40.65K |
| AccountsReceivable | 17.64K | 60.71K | 81.75K | 40.65K |
| CashCashEquivalentsAndShortTermInvestments | 2.47M | 3.45M | 10.43M | 14.87M |
| CashAndCashEquivalents | 2.47M | 3.45M | 10.43M | 14.87M |
| CashEquivalents | 2.42M | 3.35M | 6.61M | 0.00 |
| CashFinancial | 53.69K | 95.00K | 3.82M | 14.87M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -3.72M | -6.63M | -8.21M | -4.83M |
| RepaymentOfDebt | -69.72K | -66.09K | -20.41K | 0.00 |
| IssuanceOfCapitalStock | 3.50M | 0.00 | 5.00M | 18.07M |
| CapitalExpenditure | -38.92K | -46.36K | -45.70K | -31.81K |
| EndCashPosition | 2.47M | 3.45M | 10.43M | 14.87M |
| BeginningCashPosition | 3.45M | 10.43M | 14.87M | 134.52K |
| EffectOfExchangeRateChanges | -35.95K | 4.04K | -136.15K | 195.86K |
| ChangesInCash | -938.06K | -6.99M | -4.30M | 14.54M |
| FinancingCashFlow | 2.78M | -361.04K | 3.91M | 19.37M |
| CashFlowFromContinuingFinancingActivities | 2.78M | -361.04K | 3.91M | 19.37M |
| NetOtherFinancingCharges | -667.88K | -295.25K | -1.07M | -698.58K |
| ProceedsFromStockOptionExercised | 16.57K | 296.00 | 64.00 | 2.00M |
| NetCommonStockIssuance | 3.50M | 0.00 | 5.00M | 18.07M |
| CommonStockIssuance | 3.50M | 0.00 | 5.00M | 18.07M |
| NetIssuancePaymentsOfDebt | -69.72K | -66.09K | -20.41K | 0.00 |
| NetLongTermDebtIssuance | -69.72K | -66.09K | -20.41K | 0.00 |
| LongTermDebtPayments | -69.72K | -66.09K | -20.41K | 0.00 |
| InvestingCashFlow | -38.92K | -46.36K | -45.70K | -31.81K |
| CashFlowFromContinuingInvestingActivities | -38.92K | -46.36K | -45.70K | -31.81K |
| NetIntangiblesPurchaseAndSale | -38.92K | -42.05K | -26.00K | -31.81K |
| PurchaseOfIntangibles | -38.92K | -42.05K | -26.00K | -31.81K |
| NetPPEPurchaseAndSale | 0.00 | -4.31K | -19.70K | 0.00 |
| PurchaseOfPPE | 0.00 | -4.31K | -19.70K | 0.00 |
| OperatingCashFlow | -3.68M | -6.58M | -8.17M | -4.80M |
| CashFlowFromContinuingOperatingActivities | -3.68M | -6.58M | -8.17M | -4.80M |
| ChangeInWorkingCapital | 116.79K | -1.03M | 1.47M | -1.08M |
| ChangeInPayablesAndAccruedExpense | -134.45K | -1.19M | 892.26K | -259.32K |
| ChangeInPrepaidAssets | 208.17K | 142.65K | 622.60K | -794.71K |
| ChangeInReceivables | 43.07K | 21.04K | -41.10K | -29.38K |
| ChangesInAccountReceivables | 43.07K | 21.04K | -41.10K | -29.38K |
| OtherNonCashItems | 3.70K | 59.09K | ||
| StockBasedCompensation | 122.53K | 120.98K | 487.94K | 396.42K |
| ProvisionandWriteOffofAssets | 0.00 | 0.00 | ||
| AssetImpairmentCharge | 0.00 | 0.00 | ||
| DepreciationAmortizationDepletion | 117.27K | 139.69K | 58.15K | 14.27K |
| DepreciationAndAmortization | 117.27K | 139.69K | 58.15K | 14.27K |
| AmortizationCashFlow | 31.07K | 66.63K | 17.08K | 14.27K |
| AmortizationOfIntangibles | 31.07K | 66.63K | 17.08K | 14.27K |
| Depreciation | 86.20K | 73.06K | 41.07K | |
| OperatingGainsLosses | -721.90K | -3.66M | -2.47M | -2.61M |
| GainLossOnInvestmentSecurities | -756.07K | -3.64M | -2.46M | -2.64M |
| NetForeignCurrencyExchangeGainLoss | 34.18K | -13.63K | -6.39K | 28.26K |
| NetIncomeFromContinuingOperations | -3.31M | -2.16M | -7.72M | -1.58M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for XRTX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|